Heilongjiang Tianlong Pharmaceutical, a wholly-owned subsidiary of China Sky One Medical has recently completed R&D for the spray, which includes the active ingredients naphazoline hydrochloride chlorpheniramine maleate and benzalkonium bromide.
There are currently only five other manufacturers of the spray in China and China Sky One has obtained the necessary approvals for production.
Yan-Qing Liu, chairman, CEO and president of China Sky One Medical, said: “We are very excited about the development of this spray, which serves a huge market in China. We expect to launch the spray in the fourth quarter of 2008, and estimate that sales will add $500,000 to revenue in the fourth quarter.”